Institutional shares held 30.9 Million
376K calls
489K puts
Total value of holdings $18.7B
$229M calls
$297M puts
Market Cap $33.6B
55,323,800 Shares Out.
Institutional ownership 55.79%
# of Institutions 401


Latest Institutional Activity in ARGX

Top Purchases

Q3 2024
Invesco Ltd. Shares Held: 434K ($263M)
Q3 2024
Price T Rowe Associates Inc Shares Held: 5.82M ($3.53B)
Q3 2024
Capital World Investors Shares Held: 1.7M ($1.03B)
Q3 2024
Lord, Abbett & Co. LLC Shares Held: 163K ($99M)
Q3 2024
Jefferies Financial Group Inc. Shares Held: 160K ($97.2M)

Top Sells

Q3 2024
T. Rowe Price Investment Management, Inc. Shares Held: 772K ($469M)
Q3 2024
Holocene Advisors, LP Shares Held: 195K ($118M)
Q3 2024
Eventide Asset Management, LLC Shares Held: 108K ($65.7M)
Q3 2024
Alyeska Investment Group, L.P. Shares Held: 60K ($36.4M)
Q3 2024
Braidwell LP Shares Held: 96.7K ($58.7M)

About ARGX

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.


Insider Transactions at ARGX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on ARGX

Follow ARGENX SE and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARGX shares.

Notify only if

Insider Trading

Get notified when an Argenx Se insider buys or sells ARGX shares.

Notify only if

News

Receive news related to ARGENX SE

Track Activities on ARGX